Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07264660 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-07264660 | EXPERIMENTAL | Participants will receive a single dose of PF-07264660 via IV infusion |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo via IV infusion |
| Name | Type | Description |
|---|---|---|
| PF-07264660 | DRUG | PF-07264660 solution for injection (single use only) |
| Placebo | OTHER | Placebo solution for injection (single use only) |
Inclusion Criteria: 1. Healthy male and female participants aged 18 to 65 years. 2. Body mass index (BMI) of 19-27.9 kilogram per meter squared, inclusive, and a total body weight \>50 kilograms (110 pounds). 3. Participants who are willing and able to comply with all scheduled visits, treatment pl...
PF-07264660 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, with one completed trial involving 12 individuals in China.
PF-07264660 is being studied for use in healthy participants. The completed Phase 1 trial was designed to learn more about the study medicine in healthy Chinese adult participants. Its specific therapeutic indication has not been established yet, as it is still in early clinical development.
PF-07264660 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company conducted a Phase 1 clinical trial of the drug in healthy participants in China.
PF-07264660 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, with no active trials currently listed for this asset.
PF-07264660 has one completed clinical trial, identified as NCT06712082. This Phase 1 study, titled "A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants," enrolled 12 healthy volunteers in China. The trial was randomized, double-blind, and placebo-controlled.